iPSC-derived T-cell therapy (Juntendo University/University of Tokyo)

N/A

Report date: 2025/03/20 16:04:45

Base Information

Drug NameiPSC-derived T-cell therapy (Juntendo University/University of Tokyo)

Drug Alias NameHPV-rejT therapy (Juntendo University/University of Tokyo)induced pluripotent stem cell-derived T-cell therapy (Juntendo University/University of Tokyo)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionProtein E7 modulatorsProtein E6 modulators

TargetsProtein E6Protein E7

Therapy Area/IndicationsUterine Cervical Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesJuntendo University

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Tokyo Juntendo University

Inactive CompaniesN/A

Active IndicationsUterine Cervical Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A